Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Replicel Life Sciences Inc (OP: REPCF ) N/A UNCHANGED Last Price Updated: 11:20 AM EDT, Mar 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Replicel Life Sciences Inc RepliCel Provides Corporate Update November 28, 2022 Via ACCESSWIRE RepliCel Announces Material Patent Milestones in Key Markets August 04, 2022 Via ACCESSWIRE DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections August 02, 2022 Via ACCESSWIRE RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Manufacturing Inspected by Japan’s PMDA July 28, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing July 26, 2022 This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release... From RepliCel Life Sciences, Inc. Via AccessWire Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 Via ACCESSWIRE Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing July 26, 2022 Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Material Patent Milestones January 10, 2022 New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc.... From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property RepliCel Closed Final Tranche of Strategic Investment Commitment December 21, 2021 VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Terminates License Agreement with Shiseido December 21, 2021 VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing November 11, 2021 Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team November 09, 2021 RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc.... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line October 28, 2021 Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Dermal Injector Update October 27, 2021 Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE /... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021 After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021 Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC /... From RepliCel Life Sciences, Inc. Via AccessWire Topics Economy Exposures Economy RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021 - Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy... From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies July 07, 2021 Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Adds Independent Director June 15, 2021 Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2),... From RepliCel Life Sciences, Inc. Via AccessWire Topics Artificial Intelligence Exposures Artificial Intelligence RepliCel Launches Testing of Dermal Injector Units May 25, 2021 Initial units delivered and first phase of functional testing nearly complete VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ("RepliCel" or... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021 Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor May 17, 2021 Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel's Skin Rejuvenation Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map May 11, 2021 Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life... From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property RepliCel Announces Record Year in Patents Granted May 05, 2021 Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life... From RepliCel Life Sciences, Inc. Via AccessWire Topics Intellectual Property Exposures Intellectual Property RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) May 03, 2021 Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3,... From RepliCel Life Sciences, Inc. Via AccessWire RepliCel Closes Second Tranche of Strategic Investment Commitment April 29, 2021 MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP)... From RepliCel Life Sciences, Inc. Via AccessWire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.